People taking Novo Nordisk’s Wegovy® experienced reduced food noise and boosted mental well-being

Bagsværd, Denmark, 16 September 2025 – Novo Nordisk today announced results from the US-based INFORM survey of people taking semaglutide for weight management (Wegovy^®), at the European Association for the Study of Diabetes (EASD) 2025, Vienna, Austria. The INFORM survey revealed that individuals experienced a substantial drop in food noise after starting Wegovy^® treatment, alongside notable improvements in their mental well-being and lifestyle.¹ Food noise – unwanted and intrusive thoughts about food – can affect the mental well-being, quality of life and weight loss efforts of those living with overweight or obesity.²